EP0594047B1 - Chromoionophores de type arylazoique - Google Patents
Chromoionophores de type arylazoique Download PDFInfo
- Publication number
- EP0594047B1 EP0594047B1 EP93116547A EP93116547A EP0594047B1 EP 0594047 B1 EP0594047 B1 EP 0594047B1 EP 93116547 A EP93116547 A EP 93116547A EP 93116547 A EP93116547 A EP 93116547A EP 0594047 B1 EP0594047 B1 EP 0594047B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- benzothiazolyl
- pyridyl
- nitro
- chloro
- thiazolyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
- C09B29/00—Monoazo dyes prepared by diazotising and coupling
- C09B29/34—Monoazo dyes prepared by diazotising and coupling from other coupling components
- C09B29/36—Monoazo dyes prepared by diazotising and coupling from other coupling components from heterocyclic compounds
- C09B29/3604—Monoazo dyes prepared by diazotising and coupling from other coupling components from heterocyclic compounds containing only a nitrogen as heteroatom
- C09B29/3617—Monoazo dyes prepared by diazotising and coupling from other coupling components from heterocyclic compounds containing only a nitrogen as heteroatom containing a six-membered heterocyclic with only one nitrogen as heteroatom
- C09B29/3643—Monoazo dyes prepared by diazotising and coupling from other coupling components from heterocyclic compounds containing only a nitrogen as heteroatom containing a six-membered heterocyclic with only one nitrogen as heteroatom from quinolines or hydrogenated quinolines
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
Definitions
- Calcium is one of the more important elements found in the body. It is necessary not only for the skeleton but also for cells. There is, on average, about one kilogram of calcium in the human body of which 99% is located in bone with the remaining 1% distributed in plasma, extracellular fluids and intercellular compartments. This small fraction, however, plays a vital role in many biochemical and physiological functions such as a cell regulator and messenger. These functions include bone formation and homostasis, maintenance of cell membrane integrity and permeability, nerve excitation, muscular contraction and blood coagulation together with regulation of many enzyme and hormone reactions.
- PTH parathyroid hormone
- calcitonin is released from the parathyroid gland in response to a decrease of calcium concentration in plasma and indirectly promotes calcium absorption in the intestine and renal tubules and increases the calcium mobilization from bone.
- Calcitonin which inhibits PTH activity in bone tissue, is secreted by the thyroid gland in response to a rise in calcium ion.
- Deviations from normal calcium levels occur in certain diseases. Calcium levels significantly less than normal can be indicative of hypoparathyroidism, Vitamin D deficiency or nephritis. Calcium levels of greater than normal may indicate hyperparathyroidism, Vitamin D intoxication or myeloma.
- the normal value of total calcium in plasma is about 2.4 mM/l. Generally, infants have the highest calcium concentration which declines slightly with age.
- CPC ortho-cresolphthalein
- Arsenazo III forms colored complexes with many divalent and trivalent cations but can be used to determine micromolar quantities of calcium ion at pH 5.5 without significant interference from magnesium ion.
- This reagent has a high affinity for calcium ion at the physiological pH, a high extinction coefficient of the calcium-dye complex at 650 nm and exhibits high chemical stability in aqueous solutions. Accordingly it has become a useful tool for determining micromolar concentrations of calcium in single cells.
- arsenazo III is widely used by researchers in studies of calcium transport in cells and cell fractions, its utility in clinical chemistry has been limited due to the presence of toxic arsenic moieties and their concomitant safety and environmental concerns.
- Tsien reports the preparation of 2-[[2-bis (carboxymethyl)amino]-5-methylphenoxy]methyl]-8-[bis(carboxymethyl)amino]quinoline(QUIN1) and its 6-methoxy analog (QUIN2). These compounds are described as having utility as fluorescent calcium ionophores.
- Tsien et al. describe monitoring the fluorescence of QUIN2 as being the most popular method for measuring [Ca ++ ]. They go on to point out that, while QUIN2 has revealed much important biological information, its use has some inherent limitations since its preferred excitation wavelength of 339 nm is too low.
- the present invention is predicated on the discovery that arylazo derivatives of QUIN1 and QUIN2 can be effectively used for the colorimetric determination of Ca ++ since they are highly selective for calcium in media which also contain magnesium ion. Furthermore, these compounds absorb light at longer wavelengths than do similarly derivatized BAPTAs and exhibit a significantly greater shift in the maximum absorbance of the complexed -vs- non-complexed compound than do the corresponding chromogenic BAPTA compounds.
- the present invention involves arylazo calcium chromoionophores characterized by formula A:
- X is hydrogen or a monovalent cation
- Y is H or methoxy
- R is a five or six membered, substituted or unsubstituted aromatic or heteroaromatic ring or a fused ring system made up of five or six membered, substituted or unsubstituted, aromatic or heteroaromatic rings.
- calcium indicators 14 - 41 are prepared using either method 1 or 2 as mentioned herein.
- Method 1 involves coupling of an aromatic diazonium salt R-N 2 + with 1 to afford arylazo-tetraester intermediates 2 - 11 (Table 1) followed by base hydrolysis to afford the calcium indicators 14 to 23 (Table 2).
- the starting material 1 will have a 6-methoxy group.
- Method 2 first hydrolyses the esters of 1 to give 13 then couples this with the aromatic diazonium salt to afford indicators 24 - 41 .
- Method 1 has an advantage since the arylazo-tetraester intermediates are highly crystalline and easily purified by simple recrystallization. Their base hydrolysis under preferred conditions, i.e.
- Method 2 has an advantage in connection with the synthesis of certain analogs labile to the base hydrolysis conditions. Some analogs can be made by either method and representative synthetic methods are given below. All starting materials are readily available to those skilled in the art of organic synthesis.
- the 5 arylazo-BAPTA analogs ( 54 - 58 ) were prepared in order to demonstrate the superior calcium indicating characteristics of the arylazo-QUIN compounds by direct comparison of BAPTA and QUIN analogs with the same substituted arylazo moieties.
- arylazo-QUIN compounds are at all suitable for the determination of calcium in biological fluids, such as human blood or plasma, where calcium is present at high levels in a mixture containing other metal ions such as magnesium.
- Grynkiewicz et al. state that "the high effective affinity of QUIN2 for Ca ++ is ideal for measuring levels...near near 10 -7 M, but also means that at the micromolar levels or above, the dye approaches saturation and loses resolution.”
- the levels of Ca ++ can range from 1-20 mg/dl (2.5 x 10 -4 to 5 x 10 -3 M), and even with a 1:100 dilution of the sample on a typical clinical analyzer the final Ca ++ concentration will still be 2.5 x 10 -6 to 5 x 10 -5 M, which is well into the micromolar range.
- the arylazo-QUIN compounds of the present invention exhibit a linear response to calcium in serum over the range of 0-20 mg/dl with no loss of resolution when the sample is diluted 1:100 into the analytical reagent solution containing the indicator.
- Mg ++ levels in human serum are typically higher than are the calcium levels and can be as high as 2.93 mg/dl (1.2 x 10 -3 M). Interference by Mg ++ would limit the utility of the arylazo-QUIN indicators in medical diagnostics yet we have found no significant interference at levels more than 3-fold higher using reagents incorporating compounds such as 14 .
- the arylazo-QUIN compounds of the present invention can be illustrated by general formula A in which Y is hydrogen or methoxy, and X represents hydrogen or a monovalent cation, e.g. lithium, sodium, or potassium, with potassium being the preferred specie.
- the R moiety can be any of a wide variety of ringed aromatic organic structures unsubstituted or substituted with moieties such as, for example, alkyl, alkoxy, halo, cyano, nitro, aryl, heteroaryl, keto or mesyl which completes the structure of the azo dye and effects the optical absorption properties of the compounds of the present invention.
- Typical of R are:
- reaction mass was transferred to a centrifuge tube using about 2 ml n-BuOH to rinse the flask and then centrifuged at 20,000 x G for 10 minutes whereupon the supernatant was pipetted from the resulting pellet and discarded. The pellet was twice resuspended with sonication in 20 ml n-BuOH and centrifuged as above.
- the final pellet was vacuum dried overnight at ambient temperature in the centrifuge tube, powdered and transferred to a vial where it was vacuum dried for an additional 2 days at ambient temperature to give 1.03 g (90%) of the title compound ( 14 ) as a brick-red powder which retained traces of the solvent used in the workup.
- Step 2
- Impure 32 was purified by flash chromatography on a RP-2 silica gel column (Silica Gel 60 Silanized, particle size 0.063 - 0.200 mm; from E. Merck) packed and developed with a solvent mixture of CH 3 OH/H 2 O (2:3) adjusted to pH 9 with KOH. Before column application the tetraacid was suspended in a minimum volume of the developing solvent and treated with a 4 molar excess of 4 M KOH to obtain a homogenous solution. Column fractions containing pure product are collected and acidified to pH 2.5; the CH 3 OH was removed under reduced pressure and pure 32 was isolated by filtration.
- 2-amino-4-trifluoromethyl-6-chlorobenzothiazole was diazotized as described above for the preparation of 32 .
- Step 3
- 2-Aminothiazole (20 mg, 0.2 mmol) was dissolved in 200 ⁇ l HOAc and added dropwise to a stirred mixture of nitrosylsulfuric acid (32 mg, 0.25 mmol) and HOAc (200 ⁇ l) maintained in an ice bath. The mixture was stirred for 45 minutes after which a small amount of urea was added. After an initial 5 minutes the mixture was added dropwise to a stirring solution of 53 (60 mg, 0.1 mmol) in 1.0 ml H 2 O and 0.25 ml CH 3 OH, maintained at 0-5°C and allowed to react for 3 hours.
- the optical absorption maxima of the uncomplexed and complexed forms of calcium indicator compounds 14 - 41 and 43 - 49 were determined in pH 9 borate buffer. Sufficient indicator was dissolved in the buffer to produce absorbance from about 1.0 to 2.0 when measured with a UV/VIS spectrometer. For standard curvettes with 1 cm path length and 4.0 ml volume there was typically 0.15 mg to 0.35 mg of the indicator in 4.0 ml of buffer. The uncomplexed absorption maxima was determined, then about 2.0 mg of CaCl 2 (a 50 to 100 fold molar excess) was added and the complexed absorption maximum was determined.
- the performance of 14 was evaluated in a liquid reagent formulation on a Technicon AXON® analyzer.
- the reagent was composed of 100 mM borate buffer containing 100 mg/l of compound 14 .
- Instrument parameters were as follows: R1 Volume 350 ⁇ l Sample Volume 4 ⁇ l Rinse Volume 50 ⁇ l Delay 3 minutes Filter 505/750 nm Type End-point/A Decrease
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Inorganic Chemistry (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Photoreceptors In Electrophotography (AREA)
- Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Quinoline Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (10)
- Chromoionophores arylazoïques suivant la revendication 1, dans lesquels R représente un noyau carbocyclique aromatique ou hétéroaromatique penta- ou hexagonal, substitué ou non substitué, ou un système cyclique condensé constitué de noyaux carbocycliques aromatiques ou hétéro-aromatiques penta- ou hexagonaux, substitués ou non substitués.
- Chromoionophores arylazoïques suivant l'une quelconque des revendications 1 et 2, dans lesquels le noyau carbocyclique aromatique ou hétéroaromatique est substitué avec des groupements alkyle, alkoxy, halogéno, cyano, nitro, aryle, hétéroaryle, céto ou mésyle.
- Chromoionophores arylazoïques suivant l'une quelconque des revendications 1 à 3, dans lesquels R représente un noyau carbocyclique aromatique hexagonal substitué choisi dans le groupe consistant en les noyaux 2-nitrophényle 2-nitro-4-fluorophényle ; 2-nitro-4-chlorophényle ; 2-nitro-4-trifluorométhylphényle ; 2-nitro-4-cyanophényle ; 4-nitrophényle ; 2-fluoro-4-nitrophényle ; 2-chlore-4-nitrophényle ; 3-nitro-4-sulfophényle, 2,5-dichloro-4-(2'-sulfoéthylsulfonamido)phényle ; 2-méthanesulfonyl-4-nitrophényle ; 2,4-dinitrophényle ; 2-chloro-5-nitrophényle et 3,5-dinitrophényle.
- Chromoionophores arylazoïques suivant l'une quelconque des revendications 1 à 4, dans lesquels Y représente H.
- Chromoionophores arylazoïques suivant l'une quelconque des revendications 1 à 4, dans lesquels X représente le potassium.
- Chromoionophores arylazoïques suivant l'une quelconque des revendications 1 à 6, dans lesquels R représente un noyau hétéroaromatique penta- ou hexagonal choisi dans le groupe consistant en les noyaux 2-thiazolyle ; 4-méthyl-2-thiazolyle ; 4-phényl-2-thiazolyle ; 4,5-diméthyl-2-thiazolyle ; 5-nitro-2-thiazolyle ; 5-bromo-2-thiazolyle ; 4-carboxyméthyl-2-thiazolyle ; 5-nitrophénylsulfonyl-2-thiazolyle ; 2-pyridyle ; 4,6-diméthyl-2-pyridyle ; 5-chlore-2-pyridyle ; 5-brome-2-pyridyle ; 3-méthyl-2-pyridyle ; 5-bromo-3-nitro-2-pyridyle ; 3-chlore-5-trifluorométhyl-2-pyridyle ; 3,5-dichloro-2-pyridyle ; 3-mitre-2-pyridyle ; 4-pyridyle ; 2,5,6-trifluoro-3-chlore-4-pyridyle ; 2-méthoxy-5-pyridyle ; 2,6-diméthoxy-3-pyridyle ; 5-nitro-2-pyrimidyle ; 4-méthyl-2-pyrimidyle ; 4,6-diméthyl-2-pyrimidyle ; 4,6-diméthoxy-2-pyrimidyle ; 4-chloro-6-méthyl-2-pyrimidyle ; 5-méthyl-3-isoxazolyle ; 3-méthyl-5-isoxazolyle ; 3-méthyl-5-isothiazolyle ; 1-éthyl-5-pyrazolyle ; 2-(1,3,4-thiadiazolyle) ; 5-éthyl-2-(1,3,4-thiadiazolyle) et 3-phényl-5-(1,2,4-thiadiazolyle).
- Chromoionophores arylazoïques suivant l'une quelconque des revendications 1 à 6, dans lesquels R représente un système cyclique condensé constitué de noyaux carbocycliques aromatiques ou hétéroaromatiques penta- ou hexagonaux, substitués ou non substitués, choisis dans le groupe consistant en les noyaux 4-trifluorométhyl-6-chloro-2-benzothiazolyle ; l-naphtyle ; 6-(2'-hydroxyéthyloxy)-2-benzothiazolyle ; 6-tertio-butyl-2-benzothiazolyle ; 4-méthyl-5-chloro-2-benzothiazolyle ; 4,5-diméthyl-2-benzothiazolyle ; 2-benzothiazolyle ; 5-fluoro-2-benzothiazolyle ; 6-sulfo-2-benzothiazolyle ; 5,6-dichloro-2-benzothiazolyle ; 2-β-naphtothiazolyle ; 4-bromo-6-chloro-2-benzothiazolyle ; 4,5-dichloro-2-benzothiazolyle ; 6-nitro-2-benzothiazolyle ; et 4,5,6,7-tétrachloro-2-benzothiazolyle.
- Méthode pour la détection de l'ion calcium dans un liquide aqueux supposé contenir cet ion, méthode qui comprend la mise en contact du liquide avec un composé suivant l'une quelconque des revendications 1 à 8 et la détermination de la variation de la densité optique du liquide résultant de la complexation de l'ion calcium avec ledit composé.
- Système de réactifs pour la détection de l'ion calcium dans des échantillons aqueux, comprenant un composé suivant l'une quelconque des revendications 1 à 8.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/964,860 US5310888A (en) | 1992-10-22 | 1992-10-22 | Arylazo chromoionophores |
US964860 | 1992-10-22 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0594047A1 EP0594047A1 (fr) | 1994-04-27 |
EP0594047B1 true EP0594047B1 (fr) | 2000-01-05 |
Family
ID=25509095
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP93116547A Expired - Lifetime EP0594047B1 (fr) | 1992-10-22 | 1993-10-13 | Chromoionophores de type arylazoique |
Country Status (11)
Country | Link |
---|---|
US (1) | US5310888A (fr) |
EP (1) | EP0594047B1 (fr) |
JP (1) | JP3312793B2 (fr) |
AT (1) | ATE188552T1 (fr) |
AU (1) | AU663415B2 (fr) |
CA (1) | CA2104839C (fr) |
DE (1) | DE69327503T2 (fr) |
DK (1) | DK0594047T3 (fr) |
ES (1) | ES2143483T3 (fr) |
GR (1) | GR3033017T3 (fr) |
PT (1) | PT594047E (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8962338B2 (en) | 2010-03-30 | 2015-02-24 | Roche Diagnostics Operations, Inc. | Methods for measurement of calcium ions |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5501980A (en) * | 1994-05-20 | 1996-03-26 | Molecular Probes, Inc. | Benzazolylcoumarin-based ion indicators |
AT401823B (de) * | 1993-09-30 | 1996-12-27 | Avl Verbrennungskraft Messtech | Optischer indikator zur bestimmung der aktivität eines ions in einer probe |
US5914271A (en) * | 1996-04-19 | 1999-06-22 | Actimed Laboratories, Inc. | Fertility test |
US5747345A (en) * | 1996-08-15 | 1998-05-05 | Johnson & Johnson Clinical Diagnostics, Inc. | Calcium specific diaza-18-crown-6-ether chromoionophores |
US6180411B1 (en) * | 1997-08-01 | 2001-01-30 | The Regents Of The University Of California | Light-triggered indicators that memorize analyte concentrations |
AUPS255402A0 (en) * | 2002-05-27 | 2002-06-13 | Monash University | Agents and methods for the treatment of disorders associated with oxidative stress |
US6997963B2 (en) | 2002-06-28 | 2006-02-14 | L'oreal | Use of a chromoionophore and/or fluoroionophore for dyeing human keratin fibres, dyeing compositions and methods |
FR2841468B1 (fr) * | 2002-06-28 | 2004-09-10 | Oreal | Utilisation pour la teinture des fibres keratiniques humaines d'un chromoionophore et/ou un fluoroionophore, compositions et procedes de teinture |
WO2007131048A2 (fr) * | 2006-05-03 | 2007-11-15 | Opti Medical Systems, Inc. | Chromoionophore et procédé de détermination des ions de calcium |
US8540521B2 (en) | 2008-12-29 | 2013-09-24 | Life Technologies Corporation | Benzoxazole-based fluorescent metal ion indicators |
US9360474B2 (en) * | 2012-11-29 | 2016-06-07 | Opti Medical Systems, Inc. | Multi-layer device for selectively determining magnesium ion |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4689432A (en) * | 1984-09-07 | 1987-08-25 | The Regents Of The University Of California | Chelators whose affinity for calcium is decreased by illumination |
US4603209A (en) * | 1984-09-07 | 1986-07-29 | The Regents Of The University Of California | Fluorescent indicator dyes for calcium ions |
US4795712A (en) * | 1987-04-10 | 1989-01-03 | Eastman Kodak Company | Calcium complexing dyes and their use in analytical compositions, elements and methods |
US4806604A (en) * | 1987-05-13 | 1989-02-21 | Regents Of The University Of California | Photosensitive calcium chelators |
US5049673A (en) * | 1987-10-30 | 1991-09-17 | The Regents Of The University Of California | Fluorescent indicator dyes for calcium working at long wavelengths |
US5141627A (en) * | 1989-09-25 | 1992-08-25 | The Regents Of The University Of California | Chelators whose affinity for calcium ion is increased by illumination |
-
1992
- 1992-10-22 US US07/964,860 patent/US5310888A/en not_active Expired - Lifetime
-
1993
- 1993-08-25 CA CA002104839A patent/CA2104839C/fr not_active Expired - Fee Related
- 1993-10-13 EP EP93116547A patent/EP0594047B1/fr not_active Expired - Lifetime
- 1993-10-13 PT PT93116547T patent/PT594047E/pt unknown
- 1993-10-13 DE DE69327503T patent/DE69327503T2/de not_active Expired - Fee Related
- 1993-10-13 ES ES93116547T patent/ES2143483T3/es not_active Expired - Lifetime
- 1993-10-13 AT AT93116547T patent/ATE188552T1/de not_active IP Right Cessation
- 1993-10-13 DK DK93116547T patent/DK0594047T3/da active
- 1993-10-20 AU AU49156/93A patent/AU663415B2/en not_active Ceased
- 1993-10-21 JP JP26347893A patent/JP3312793B2/ja not_active Expired - Fee Related
-
2000
- 2000-03-21 GR GR20000400703T patent/GR3033017T3/el not_active IP Right Cessation
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8962338B2 (en) | 2010-03-30 | 2015-02-24 | Roche Diagnostics Operations, Inc. | Methods for measurement of calcium ions |
Also Published As
Publication number | Publication date |
---|---|
DE69327503D1 (de) | 2000-02-10 |
ES2143483T3 (es) | 2000-05-16 |
US5310888A (en) | 1994-05-10 |
EP0594047A1 (fr) | 1994-04-27 |
ATE188552T1 (de) | 2000-01-15 |
JP3312793B2 (ja) | 2002-08-12 |
CA2104839A1 (fr) | 1994-04-23 |
DK0594047T3 (da) | 2000-06-19 |
CA2104839C (fr) | 2002-07-02 |
PT594047E (pt) | 2000-06-30 |
DE69327503T2 (de) | 2000-08-24 |
AU663415B2 (en) | 1995-10-05 |
JPH06207932A (ja) | 1994-07-26 |
GR3033017T3 (en) | 2000-08-31 |
AU4915693A (en) | 1994-05-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0594047B1 (fr) | Chromoionophores de type arylazoique | |
US5501980A (en) | Benzazolylcoumarin-based ion indicators | |
US5648270A (en) | Methods of sensing with fluorescent conjugates of metal-chelating nitrogen heterocycles | |
CA1305133C (fr) | Ionophores fluorogeniques et chromogeniques a trois dimensions, utilises comme reactifs selectifs pour la detection d'ions dans les liquides biologiques | |
US5459276A (en) | Benzazolylcoumarin-based ion indicators for heavy metals | |
US7335771B2 (en) | Quinacridone derivatives as labelling reagents for fluorescence detection of biological materials | |
EP0517055B1 (fr) | Mérocynanines comme indicateurs d'erreur de protéine | |
JPH04231866A (ja) | イオン測定用試験担体 | |
CA2754169A1 (fr) | Derives d'acridone utilises comme etiquettes dans la detection par fluorescence de materiaux cibles | |
JPS58134097A (ja) | カリウム試薬およびカリウムイオンの分析方法 | |
RU2400481C2 (ru) | Водорастворимые тетразолиевые соли | |
CA1258672A (fr) | Colorants formant des complexes avec le calcium; leur utilisation dans des compositions, des elements et des methodes analytiques | |
US20080312431A1 (en) | Responsive Luminescent Lanthanide Complexes | |
JP2749615B2 (ja) | 新規な指示薬化合物、その製造法及び鉄分析系における該化合物の使用 | |
AU650804B2 (en) | Colorimetric methods and reagents for the assay of calcium in a test sample | |
US20070259438A1 (en) | Chromoionophore and method of determining calcium ions | |
IL99351A (en) | Colorimetric method and reagent for determining lithium in an experimental sample | |
JP2665412B2 (ja) | 高感度のイオン測定方法、該方法に適する物質の使用および対応する試薬 | |
WO2007131054A2 (fr) | Chromoionophore et procédé de détermination d'ions de sodium | |
US5194389A (en) | Naphthol derivatives, processes for their production and their use | |
CN115490664B (zh) | 一类选择性检测同型半胱氨酸的荧光探针的合成及应用 | |
JPH01112155A (ja) | 過酸化水素の定量方法及びその定量用試薬 | |
JPH0588788B2 (fr) | ||
SU833539A1 (ru) | Способ фотометрического определени мо-либдЕНА | |
Akumu et al. | Aqueous Fluoride Rapid Detection based on TBAF Desilylation by a Novel Fluorogenic 7-O-tert-butyldimethylsylyl-2-(hydroxyimino)-4-methyl-2H-chromene-3-carbonitrile |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE |
|
17P | Request for examination filed |
Effective date: 19940920 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: BAYER CORPORATION |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: BAYER CORPORATION |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: BAYER CORPORATION |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
17Q | First examination report despatched |
Effective date: 19990215 |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE |
|
REF | Corresponds to: |
Ref document number: 188552 Country of ref document: AT Date of ref document: 20000115 Kind code of ref document: T |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: E. BLUM & CO. PATENTANWAELTE Ref country code: CH Ref legal event code: EP |
|
REF | Corresponds to: |
Ref document number: 69327503 Country of ref document: DE Date of ref document: 20000210 |
|
ET | Fr: translation filed | ||
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
ITF | It: translation for a ep patent filed |
Owner name: ING. C. GREGORJ S.P.A. |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2143483 Country of ref document: ES Kind code of ref document: T3 |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: SC4A Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20000329 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed | ||
REG | Reference to a national code |
Ref country code: GB Ref legal event code: IF02 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20050916 Year of fee payment: 13 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: AT Payment date: 20050921 Year of fee payment: 13 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: PT Payment date: 20050922 Year of fee payment: 13 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20051005 Year of fee payment: 13 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20051017 Year of fee payment: 13 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IE Payment date: 20051026 Year of fee payment: 13 Ref country code: ES Payment date: 20051026 Year of fee payment: 13 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20051027 Year of fee payment: 13 Ref country code: CH Payment date: 20051027 Year of fee payment: 13 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GR Payment date: 20051031 Year of fee payment: 13 Ref country code: DK Payment date: 20051031 Year of fee payment: 13 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: LU Payment date: 20051104 Year of fee payment: 13 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20051122 Year of fee payment: 13 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20051130 Year of fee payment: 13 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20061013 Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20061013 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20061014 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20061031 Ref country code: DK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20061031 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20061031 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20061031 Year of fee payment: 14 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20070413 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20070501 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20070501 |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: MM4A Free format text: LAPSE DUE TO NON-PAYMENT OF FEES Effective date: 20070413 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
EUG | Se: european patent has lapsed | ||
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20061013 |
|
NLV4 | Nl: lapsed or anulled due to non-payment of the annual fee |
Effective date: 20070501 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20070629 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20061013 |
|
BERE | Be: lapsed |
Owner name: *BAYER CORP. Effective date: 20061031 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20061014 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20061031 Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20061014 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20061013 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20070503 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20071013 Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20061031 |